Articles
Page 2 of 20
-
Citation: BMC Pharmacology 2011 11(Suppl 2):A59
-
The G protein-coupled receptor-associated protein 1 (GASP-1) regulates rimonabant-induced downregulation of GPR55
Citation: BMC Pharmacology 2011 11(Suppl 2):A57 -
The rise and fall of CB1 receptor antagonists: possible future perspectives
Citation: BMC Pharmacology 2011 11(Suppl 2):A55 -
Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice
Citation: BMC Pharmacology 2011 11(Suppl 2):A53 -
Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [11C]tariquidar and PET
Citation: BMC Pharmacology 2011 11(Suppl 2):A48 -
Fear learning induces structural and functional plasticity at GABAergic synapses in the basolateral amygdala
Citation: BMC Pharmacology 2011 11(Suppl 2):A42 -
Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment
Citation: BMC Pharmacology 2011 11(Suppl 2):A40 -
ABC transporters of Fasciola hepatica as putative drug targets
Citation: BMC Pharmacology 2011 11(Suppl 2):A36 -
Urea induces intercellular adhesion molecule-1 expression
Citation: BMC Pharmacology 2011 11(Suppl 2):A34 -
Uremic albumin blocks reverse cholesterol transfer: role of lysine modifications
Citation: BMC Pharmacology 2011 11(Suppl 2):A32 -
Differential modulation of rNaV1.4 channel inactivated states by lidocaine and its charged analogue QX222
Citation: BMC Pharmacology 2011 11(Suppl 2):A30 -
Current-clamp experiments on primary hippocampal neurons shed light on the role of L-type voltage-gated calcium channels in depolarization shifts
Citation: BMC Pharmacology 2011 11(Suppl 2):A28 -
Introduction of a 6-cyano group in 14-oxygenated N-methylmorphinans influences in vitro and in vivo pharmacological activities
Citation: BMC Pharmacology 2011 11(Suppl 2):A26 -
Interaction of V-type ATPase inhibitors and extracellular NAADP-triggered calcium release in skeletal muscle cells
Citation: BMC Pharmacology 2011 11(Suppl 2):A24 -
The transcription factor STAT5 drives mutation and imatinib resistance in chronic myeloid leukemia via ROS production
Citation: BMC Pharmacology 2011 11(Suppl 2):A22 -
Truncations in the amino terminus reveal a region key to supporting amphetamine-induced efflux by the human serotonin transporter
Citation: BMC Pharmacology 2011 11(Suppl 2):A20 -
Novel pyrazole inhibitors for discrimination between receptor-operated and store-operated Ca2+ entry
Citation: BMC Pharmacology 2011 11(Suppl 2):A18 -
Circular plant peptides as templates for GPCR drug discovery?
Citation: BMC Pharmacology 2011 11(Suppl 2):A16 -
Morphological characterization of large intercalated neurons provides novel insight on intrinsic networks of the amygdala
Citation: BMC Pharmacology 2011 11(Suppl 2):A9 -
Pharmacoepidemiological aspects of outpatient pain medication
Citation: BMC Pharmacology 2011 11(Suppl 2):A8 -
PI3Kδ is indispensable for CTL-mediated cytotoxicity
Citation: BMC Pharmacology 2011 11(Suppl 2):A7 -
Treprostinil stimulates the engraftment of haematopoetic stem cells
Citation: BMC Pharmacology 2011 11(Suppl 2):A6 -
Towards the development of novel Trypanosoma brucei RNA editing ligase 1 inhibitors
Trypanosoma brucei (T. brucei) is an infectious agent for which drug development has been largely neglected. We here use a recently developed computer program called AutoGrow to add interacting molecular fragment...
Citation: BMC Pharmacology 2011 11:9 -
Differential phosphorylation of LZ+/LZ- MYPT1 isoforms by PKGIα: implication for vascular reactivity
Citation: BMC Pharmacology 2011 11(Suppl 1):P78 -
PDE2, a component of the NO/cGMP signalling in the hippocampus
Citation: BMC Pharmacology 2011 11(Suppl 1):P63 -
Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil could salvage ED-patients with insufficient response to PDE5 inhibitors after cavernous nerve injury
Citation: BMC Pharmacology 2011 11(Suppl 1):P59 -
Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
Citation: BMC Pharmacology 2011 11(Suppl 1):P57 -
NO-donors induce cross talk between cGMP and cAMP in signalling to human atrial L-type Ca2+ current
Citation: BMC Pharmacology 2011 11(Suppl 1):P55 -
A structural analysis of the regulatory domain from the cGMP-dependent protein kinase Iα
Citation: BMC Pharmacology 2011 11(Suppl 1):P53 -
Distinct ageing- and androgen-dependent effects on cGMP signalling proteins in three male rat urogenital organs (bladder, prostate, epididymis)
Citation: BMC Pharmacology 2011 11(Suppl 1):P51 -
The mechanism of CNP-induced negative inotropic and positive lusitropic responses are dependent on SERCA activity in failing rat ventricle
Citation: BMC Pharmacology 2011 11(Suppl 1):P49 -
Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
Citation: BMC Pharmacology 2011 11(Suppl 1):P47 -
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
Citation: BMC Pharmacology 2011 11(Suppl 1):P43 -
Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
Citation: BMC Pharmacology 2011 11(Suppl 1):P41 -
Effects of riociguat in severe experimental pulmonary hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):P39 -
Role of cGMP/PKG in fat tissue
Citation: BMC Pharmacology 2011 11(Suppl 1):O35 -
NO resistance in angiotensin II–induced hypertension is associated with S-nitrosation of soluble guanylyl cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):O33 -
Fertility in male mice lacking NO-sensitive guanylyl cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):P30 -
Transformer (Tra2β): master regulator of myosin phosphatase alternative splicing and smooth muscle responses to NO/cGMP signaling
Citation: BMC Pharmacology 2011 11(Suppl 1):P24 -
Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
Citation: BMC Pharmacology 2011 11(Suppl 1):P22 -
Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?
Citation: BMC Pharmacology 2011 11(Suppl 1):O20 -
Study on the involvement of soluble guanylyl cyclase and its different isoforms in carbon monoxide and carbon monoxide releasing molecule-2 induced vasodilatation
Citation: BMC Pharmacology 2011 11(Suppl 1):P20 -
Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
Citation: BMC Pharmacology 2011 11(Suppl 1):P18 -
Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease
Citation: BMC Pharmacology 2011 11(Suppl 1):O16 -
Atrial natriuretic peptide increases the albumin permeability of mouse skeletal muscle microcirculation by the caveolae-mediated transcellular pathway
Citation: BMC Pharmacology 2011 11(Suppl 1):P16 -
PKA: assembly of dynamic macromolecular signaling
Citation: BMC Pharmacology 2011 11(Suppl 1):O12 -
Molecular aspects of sGC regulation
Citation: BMC Pharmacology 2011 11(Suppl 1):O10 -
Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
Citation: BMC Pharmacology 2011 11(Suppl 1):P10 -
Biomarkers in kidney and heart disease
Citation: BMC Pharmacology 2011 11(Suppl 1):O4 -
New clinical results with sGC stimulators
Citation: BMC Pharmacology 2011 11(Suppl 1):O2